Cargando…
Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy
BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was lo...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640848/ https://www.ncbi.nlm.nih.gov/pubmed/38026537 http://dx.doi.org/10.2147/IJN.S420802 |
_version_ | 1785133842160418816 |
---|---|
author | Min, Simin Tao, Weiting Miao, Yuchen Li, Yan Wu, Tianyu He, Xiaoyu Zhang, Yijing Liu, Bangye Meng, Zixin Han, Ke Liu, Saisai Li, Li Chen, Jie Zhao, Shidi Zhang, Junjie Zhang, Xiaonan |
author_facet | Min, Simin Tao, Weiting Miao, Yuchen Li, Yan Wu, Tianyu He, Xiaoyu Zhang, Yijing Liu, Bangye Meng, Zixin Han, Ke Liu, Saisai Li, Li Chen, Jie Zhao, Shidi Zhang, Junjie Zhang, Xiaonan |
author_sort | Min, Simin |
collection | PubMed |
description | BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was low. PURPOSE: To explore the potential of the soft mesoporous organic silica nanoplatform (NPs) as carriers for delivery of TMP and miR-194-5p through the tail vein. METHODS: NPs@TMP and NPs@PEI@miR-194-5p were added to the HUVEC cell-lines, in vitro, to observe the cell uptake and cytotoxic effects. In vivo experiments were conducted by injecting fluorescently labeled NPs through the tail vein and tracking distribution. Therapeutic and toxic side-effects were analyzed systemically. RESULTS: In vitro study exhibited that NPs have no toxic effect on HUVECs within the experimental parameters and have excellent cellular uptake. The IVIS Spectrum Imaging System shows that NPs accumulate mainly in the lungs. NPs@TMP treatment can improved oxidative stress and inflammation levels in ALI mice and inhibited the TLR4/NLRP3/caspase 1 pathway. NPs@PEI@miR-194-5p can inhibit the Rac1/ZO-1/occludin pathway and improved endothelial cell permeability in ALI mice. The co-treatment of NPs@TMP and NPs@PEI@miR-194-5p can significantly improved the survival rates of the mice, reduced pulmonary capillary permeability and improved pathological injury in ALI mice. INNOVATION: This study combined traditional Chinese medicine, bioinformatics, cellular molecular biology and nanobiomedicine to study the pathogenesis and treatment of ALI. The rate of cellular internalization was improved by changing the shape and hardness of nanoparticles. NPs@TMP and NPs@PEI@miR-194-5p combined application can significantly improve the survival condition and pathological injury of mice. CONCLUSION: NPs loaded with TMP and miR-194-5p showed a greater therapeutic effect in ALI mice. |
format | Online Article Text |
id | pubmed-10640848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-106408482023-11-08 Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy Min, Simin Tao, Weiting Miao, Yuchen Li, Yan Wu, Tianyu He, Xiaoyu Zhang, Yijing Liu, Bangye Meng, Zixin Han, Ke Liu, Saisai Li, Li Chen, Jie Zhao, Shidi Zhang, Junjie Zhang, Xiaonan Int J Nanomedicine Original Research BACKGROUND: The respiratory system is intensely damaged by acute lung injury (ALI). The anti-inflammatory effects of tetramethylpyrazine (TMP) against ALI have been confirmed, but it exhibits a short half-life. miR-194-5p could directly target Rac1, but the internalization rate of miRNA cells was low. PURPOSE: To explore the potential of the soft mesoporous organic silica nanoplatform (NPs) as carriers for delivery of TMP and miR-194-5p through the tail vein. METHODS: NPs@TMP and NPs@PEI@miR-194-5p were added to the HUVEC cell-lines, in vitro, to observe the cell uptake and cytotoxic effects. In vivo experiments were conducted by injecting fluorescently labeled NPs through the tail vein and tracking distribution. Therapeutic and toxic side-effects were analyzed systemically. RESULTS: In vitro study exhibited that NPs have no toxic effect on HUVECs within the experimental parameters and have excellent cellular uptake. The IVIS Spectrum Imaging System shows that NPs accumulate mainly in the lungs. NPs@TMP treatment can improved oxidative stress and inflammation levels in ALI mice and inhibited the TLR4/NLRP3/caspase 1 pathway. NPs@PEI@miR-194-5p can inhibit the Rac1/ZO-1/occludin pathway and improved endothelial cell permeability in ALI mice. The co-treatment of NPs@TMP and NPs@PEI@miR-194-5p can significantly improved the survival rates of the mice, reduced pulmonary capillary permeability and improved pathological injury in ALI mice. INNOVATION: This study combined traditional Chinese medicine, bioinformatics, cellular molecular biology and nanobiomedicine to study the pathogenesis and treatment of ALI. The rate of cellular internalization was improved by changing the shape and hardness of nanoparticles. NPs@TMP and NPs@PEI@miR-194-5p combined application can significantly improve the survival condition and pathological injury of mice. CONCLUSION: NPs loaded with TMP and miR-194-5p showed a greater therapeutic effect in ALI mice. Dove 2023-11-08 /pmc/articles/PMC10640848/ /pubmed/38026537 http://dx.doi.org/10.2147/IJN.S420802 Text en © 2023 Min et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Min, Simin Tao, Weiting Miao, Yuchen Li, Yan Wu, Tianyu He, Xiaoyu Zhang, Yijing Liu, Bangye Meng, Zixin Han, Ke Liu, Saisai Li, Li Chen, Jie Zhao, Shidi Zhang, Junjie Zhang, Xiaonan Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title | Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title_full | Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title_fullStr | Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title_full_unstemmed | Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title_short | Dual Delivery of Tetramethylpyrazine and miR-194-5p Using Soft Mesoporous Organosilica Nanoparticles for Acute Lung Injury Therapy |
title_sort | dual delivery of tetramethylpyrazine and mir-194-5p using soft mesoporous organosilica nanoparticles for acute lung injury therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640848/ https://www.ncbi.nlm.nih.gov/pubmed/38026537 http://dx.doi.org/10.2147/IJN.S420802 |
work_keys_str_mv | AT minsimin dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT taoweiting dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT miaoyuchen dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT liyan dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT wutianyu dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT hexiaoyu dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT zhangyijing dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT liubangye dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT mengzixin dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT hanke dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT liusaisai dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT lili dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT chenjie dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT zhaoshidi dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT zhangjunjie dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy AT zhangxiaonan dualdeliveryoftetramethylpyrazineandmir1945pusingsoftmesoporousorganosilicananoparticlesforacutelunginjurytherapy |